MELA Sciences – MelaFind Pre-Market approval

MELA Sciences, Inc. (NASDAQ:MELA). Last Market Price: 5.06, Change: +1.88, % Change: (59.12%). Shares trade in the range of 4.95 – 6.20 dollars. It has a market capitalization of 127.83M dollars, making it a Small Cap Stock and has 25.26M outstanding shares. The company has a beta of 0.97, indicating, the stock to be less volatile than the market. As per the most recent quarterly report, the net income per share (EPS) is -0.79. It operates in Healthcare sector and belongs to Medical Equipment and Supplies industry. Percentage shares held by institutional investors is 29%. The company has a 52 week high of $ 8.32 and a 52 week low of $ 1.75. Average volumes of shares traded daily are 814,143. Volume traded in the last session was at 3,160,000, 3.88 times the average volume.

• FDA has issued an approval letter for the MelaFind Pre-Market approval application

For Q2 (Jun ’11), Other Key stats and ratios are : Return on average assets of -72.82%, Return on average equity of -77.46%. The organization has an employee strength of 42

Consensus Recommendation is a Buy.

Estimate for sales for the Quarter Ending Sep-11 show a mean of 0.47 million dollars, an estimate high of 1.41 million dollars and an estimate low of 0.00 million dollars. A year ago the figures stood at 1.89 million dollars.

Estimate for sales for the Quarter Ending Dec-11 show a mean of 1.03 million dollars, an estimate high of 2.88 million dollars and an estimate low of 0.00 million dollars. A year ago the figures stood at 3.52 million dollars.

Estimate for EPS for the Quarter Ending Sep-11 show a mean of -0.23 dollars, an estimate high of -0.22 dollars and an estimate low of -0.24 dollars. A year ago the figures stood at -0.26 dollars.

Estimate for EPS for the Quarter Ending Dec-11 show a mean of -0.23 dollars, an estimate high of -0.20 dollars and an estimate low of -0.25 dollars. A year ago the figures stood at -0.22 dollars.

Sales for Quarter Ending Mar-11 was estimated at 0.61 million dollars, however the actual sales figure stood at 0.00 million dollars, 0.61 million dollars less than estimates.

Post Written By: Ed Liston Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications. He is widely quoted in various financial publications on the Internet. When Ed is not writing about stocks, investing in stocks, talking about stocks, or otherwise doing something stock related, he likes to go sailing and fishing in his yacht.